MXPA99001870A - Non-peptide tachykinin receptor antagonists. - Google Patents
Non-peptide tachykinin receptor antagonists.Info
- Publication number
- MXPA99001870A MXPA99001870A MXPA99001870A MX9901870A MXPA99001870A MX PA99001870 A MXPA99001870 A MX PA99001870A MX PA99001870 A MXPA99001870 A MX PA99001870A MX 9901870 A MX9901870 A MX 9901870A MX PA99001870 A MXPA99001870 A MX PA99001870A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor antagonists
- tachykinin receptor
- peptide tachykinin
- compounds
- peptide
- Prior art date
Links
- 239000002462 tachykinin receptor antagonist Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000003141 Tachykinin Human genes 0.000 abstract 1
- 150000001907 coumarones Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 150000002475 indoles Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108060008037 tachykinin Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
Abstract
This invention provides a series of substituted benzofurans and indoles useful as non-peptide tachykinin receptor antagonists. This invention also provides methods for treating or preventing conditions associated with an excess of tachykinins which methods comprise administration of one or more of the compounds of the instant invention as well as formulations employing the compounds of this invention.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17113493A | 1993-12-21 | 1993-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA99001870A true MXPA99001870A (en) | 2004-09-06 |
Family
ID=22622667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA99001870A MXPA99001870A (en) | 1993-12-21 | 1999-02-25 | Non-peptide tachykinin receptor antagonists. |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0736007A4 (en) |
| JP (1) | JPH09506898A (en) |
| AU (1) | AU1339795A (en) |
| CA (1) | CA2176130A1 (en) |
| MX (1) | MXPA99001870A (en) |
| WO (1) | WO1995017382A1 (en) |
| ZA (1) | ZA9410040B (en) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5492927A (en) * | 1993-12-21 | 1996-02-20 | Eli Lilly And Company | Non-peptide tachykinin receptor antagonists to treat allergy |
| WO1995017095A1 (en) * | 1993-12-21 | 1995-06-29 | Eli Lilly And Company | Methods for the treatment or prevention of conditions associated with amyloidogenic reptides |
| IL115582A0 (en) * | 1994-10-14 | 1996-01-19 | Lilly Co Eli | Methods for treating resistant tumors |
| IL115613A0 (en) * | 1994-10-20 | 1996-01-19 | Lilly Co Eli | Bicyclic neuropeptide y receptor antagonists |
| WO1996012488A1 (en) * | 1994-10-20 | 1996-05-02 | Eli Lilly And Company | Bicyclic bradykinin receptor antagonists |
| US6458811B1 (en) | 1996-03-26 | 2002-10-01 | Eli Lilly And Company | Benzothiophenes formulations containing same and methods |
| PT910369E (en) * | 1996-03-26 | 2010-06-04 | Lilly Co Eli | Benzothiophenes, formulations containing same, and methods |
| CA2206752A1 (en) | 1996-07-02 | 1998-01-02 | George Joseph Cullinan | Benzothiophene compounds, intermediates, processes, and methods of use |
| DE69824410T2 (en) | 1997-04-30 | 2005-06-02 | Eli Lilly And Co., Indianapolis | Antithrombotic agents |
| JP2002514217A (en) | 1997-04-30 | 2002-05-14 | イーライ・リリー・アンド・カンパニー | Antithrombotic substance |
| CA2287993A1 (en) | 1997-04-30 | 1998-11-05 | Mary George Johnson | Antithrombotic agents |
| EP1027051B1 (en) | 1997-04-30 | 2005-01-05 | Eli Lilly And Company | Antithrombotic agents |
| US6284756B1 (en) | 1998-04-30 | 2001-09-04 | Eli Lilly And Company | Antithrombotic agents |
| DE69904427T2 (en) * | 1998-10-28 | 2003-07-17 | Eli Lilly And Co., Indianapolis | Benzothiophene derivatives as antithrombotic agents and intermediates |
| WO2001032625A1 (en) | 1999-11-03 | 2001-05-10 | Du Pont Pharmaceuticals Company | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
| US7163949B1 (en) | 1999-11-03 | 2007-01-16 | Amr Technology, Inc. | 4-phenyl substituted tetrahydroisoquinolines and use thereof |
| CA2415532C (en) | 2000-07-11 | 2010-05-11 | Albany Molecular Research, Inc. | Novel 4-phenyl substituted tetrahydroisoquinolines therapeutic use thereof |
| ES2259376T3 (en) | 2001-05-22 | 2006-10-01 | Eli Lilly And Company | 1,2,3,4-TETRAHYDROQUINOLINS 2-SUBSTITUTES AND THEIR DERIVATIVES, COMPOSITIONS AND PROCEDURES. |
| ES2236536T3 (en) | 2001-05-22 | 2005-07-16 | Eli Lilly And Company | TETRAHYDROQUINOLINE DERIVATIVES FOR THE INHIBITION OF DISEASES ASSOCIATED WITH THE PRIVACY OF STROGENS OR WITH AN OPEN PHYSIOLOGICAL RESPONSE TO ENDOGENOUS STROGENS. |
| GB0130305D0 (en) * | 2001-12-19 | 2002-02-06 | Amersham Plc | Compounds for imaging alzheimers disease |
| UA91341C2 (en) | 2004-07-15 | 2010-07-26 | Амр Текнолоджи, Інк. | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| WO2006123182A2 (en) | 2005-05-17 | 2006-11-23 | Merck Sharp & Dohme Limited | Cyclohexyl sulphones for treatment of cancer |
| NZ565111A (en) | 2005-07-15 | 2011-10-28 | Amr Technology Inc | Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| WO2007041052A2 (en) | 2005-09-29 | 2007-04-12 | Merck & Co., Inc. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| WO2008039327A2 (en) | 2006-09-22 | 2008-04-03 | Merck & Co., Inc. | Method of treatment using fatty acid synthesis inhibitors |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| EP2805945B1 (en) | 2007-01-10 | 2019-04-03 | MSD Italia S.r.l. | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors |
| JP5319518B2 (en) | 2007-04-02 | 2013-10-16 | Msd株式会社 | Indoledione derivative |
| AU2008269154B2 (en) | 2007-06-27 | 2014-06-12 | Merck Sharp & Dohme Llc | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| CA2717509A1 (en) | 2008-03-03 | 2009-09-11 | Tiger Pharmatech | Tyrosine kinase inhibitors |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
| EP2429295B1 (en) | 2009-05-12 | 2013-12-25 | Albany Molecular Research, Inc. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
| EA020553B1 (en) | 2009-05-12 | 2014-12-30 | Олбани Молекьюлар Рисерч, Инк. | 7-([1,2,4]TRIAZOLO[1,5-α]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS OF TREATING NEUROLOGICAL AND MENTAL DISORDERS |
| KR20120023072A (en) | 2009-05-12 | 2012-03-12 | 브리스톨-마이어스 스큅 컴퍼니 | Crystalline forms of (s)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorohphenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
| CN102638981B (en) | 2009-10-14 | 2015-07-22 | 默沙东公司 | Substituted piperidines for enhancing p53 activity and uses thereof |
| US8999957B2 (en) | 2010-06-24 | 2015-04-07 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as ERK inhibitors |
| EP2601293B1 (en) | 2010-08-02 | 2017-12-06 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| WO2012024170A2 (en) | 2010-08-17 | 2012-02-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
| WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| EP3766975A1 (en) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| IN2013MN02170A (en) | 2011-04-21 | 2015-06-12 | Piramal Entpr Ltd | |
| US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
| EP3919620A1 (en) | 2012-05-02 | 2021-12-08 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
| RU2660429C2 (en) | 2012-09-28 | 2018-07-06 | Мерк Шарп И Доум Корп. | Novel compounds that are erk inhibitors |
| PL2925888T3 (en) | 2012-11-28 | 2018-03-30 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
| KR102196882B1 (en) | 2012-12-20 | 2020-12-30 | 머크 샤프 앤드 돔 코포레이션 | Substituted imidazopyridines as hdm2 inhibitors |
| WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
| US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| EP3525785B1 (en) | 2016-10-12 | 2025-08-27 | Merck Sharp & Dohme LLC | Kdm5 inhibitors |
| EP3706747B1 (en) | 2017-11-08 | 2025-09-03 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| MA53287A (en) | 2018-08-07 | 2022-05-11 | Merck Sharp & Dohme | PRMT5 INHIBITORS |
| EP3833668B1 (en) | 2018-08-07 | 2025-03-19 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1138163A (en) * | 1965-05-21 | 1968-12-27 | Bristol Myers Co | Benzothiophene derivatives having anti-fertility properties |
| US3975537A (en) * | 1973-09-21 | 1976-08-17 | Smith Kline | Pharmaceutical compositions and methods of producing coronary vasodilation |
| US3880891A (en) * | 1973-09-21 | 1975-04-29 | Smithkline Corp | Substituted benzofurans |
| US3947470A (en) * | 1974-06-20 | 1976-03-30 | Smithkline Corporation | Substituted benzofurans and benzothiophenes |
| US4024273A (en) * | 1974-06-20 | 1977-05-17 | Smithkline Corporation | Coronary vasodilator and anti-anginal compositions comprising substituted benzofurans and benzothiophenes and methods of producing coronary vasodilation and anti-anginal activity |
| US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
| US4230862A (en) * | 1975-10-28 | 1980-10-28 | Eli Lilly And Company | Antifertility compounds |
| US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
-
1994
- 1994-12-14 WO PCT/US1994/014312 patent/WO1995017382A1/en not_active Ceased
- 1994-12-14 AU AU13397/95A patent/AU1339795A/en not_active Abandoned
- 1994-12-14 JP JP7517478A patent/JPH09506898A/en active Pending
- 1994-12-14 CA CA002176130A patent/CA2176130A1/en not_active Abandoned
- 1994-12-14 EP EP95904891A patent/EP0736007A4/en not_active Withdrawn
- 1994-12-15 ZA ZA9410040A patent/ZA9410040B/en unknown
-
1999
- 1999-02-25 MX MXPA99001870A patent/MXPA99001870A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO1995017382A1 (en) | 1995-06-29 |
| JPH09506898A (en) | 1997-07-08 |
| ZA9410040B (en) | 1996-06-18 |
| AU1339795A (en) | 1995-07-10 |
| EP0736007A4 (en) | 1997-03-19 |
| CA2176130A1 (en) | 1995-06-29 |
| EP0736007A1 (en) | 1996-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA99001870A (en) | Non-peptide tachykinin receptor antagonists. | |
| IL111615A0 (en) | Non-peptide tachykinin receptor antagonists | |
| ES2072096T3 (en) | 4-PHENYLPIPERIDINES N-SUBSTITUTED OPIOID ANTAGONISTS. | |
| EP0766559A4 (en) | Cannabinoid receptor antagonists | |
| YU59098A (en) | Substituted spiro-piperidine derivatives | |
| MX9706969A (en) | 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists. | |
| NO903455L (en) | ANALOGS OF LUTE INHIBITING HORMON AND PREPARATION HORMON. | |
| YU15299A (en) | Pharmaceutical compositions | |
| AUPO755097A0 (en) | Receptor agonist and antagonist | |
| MX9805253A (en) | Vitronectin receptor antagonists. | |
| GR3019782T3 (en) | Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents | |
| MX9801890A (en) | Novel human nk3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them. | |
| DE69330754D1 (en) | 2,5-DIOXO-2,5-DIHYDRO-1H-BENZ [b] AZEPINE AS AN NMDA RECEPTOR ANTAGONIST | |
| EA199800867A1 (en) | COMPOUNDS TETRAHYDROBETAKARBOLINA | |
| IL128500A0 (en) | Substituted 1,2,3,4-tetrahydro-2-dibenzofuranamines and 2-aminocyclohepta (b) benzofurans | |
| MY107354A (en) | Substituted cyclohexenes as central nervous system agents | |
| ATE282417T1 (en) | THE USE OF NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MOVEMENT DISORDERS | |
| EA200100182A1 (en) | TREATMENT OF CONDITION OF ANXIETY | |
| BG102229A (en) | Endothelium receptor antagonists | |
| ATE282416T1 (en) | THE USE OF NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SUBSTANCE USE DISORDERS | |
| TR200000287T2 (en) | 2-acylaminopropanamines as tachykinin receptor antagonists. | |
| EP0707852A3 (en) | Bicyclic bradykinin receptor antagonists | |
| EA199800204A1 (en) | 5-Ht 3? receptor antagonists for dyskinesia | |
| MX9706967A (en) | Indazolecarboxamides. |